The race for new, long-lasting treatments for the two most common forms of hemophilia heated up this week as two local gene therapy companies presented trial data for drugs in development alongside Big Pharma players.
Lexington biotech UniQure N.V. (Nasdaq: QURE) — which has been the subject of M&A rumors in recent weeks, per Bloomberg — presented new data earlier this week on its treatment for hemophilia B, a form of the rare, genetic blood disease which affects the body’s ability to form…
